Li Wang Xiaomo Li Yurong Cheng Jing Yang Si Liu Tonghui Ma Li Luo Yanping Hu Yi Cai Dong Yan
10.3389/fimmu.2021.784861
Front Immunol
2022 Jan 6;12:784861.
her2 amplification camrelizumab case report combination immunotherapy gallbladder cancer irae trastuzumab resistance
CC BY
https://pubmed.ncbi.nlm.nih.gov/35069555/
Antibodies, Monoclonal, Humanized / administration & dosage Drug Resistance, Neoplasm / drug effects Gallbladder Neoplasms / drug therapy Gallbladder Neoplasms / enzymology Gallbladder Neoplasms / pathology Receptor, ErbB-2 / antagonists & inhibitors Trastuzumab / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage Drug Resistance, Neoplasm / drug effects Gallbladder Neoplasms / drug therapy Gallbladder Neoplasms / enzymology Gallbladder Neoplasms / pathology Receptor, ErbB-2 / antagonists & inhibitors Trastuzumab / administration & dosage Case Reports Aged Humans Male Neoplasm Metastasis Antibodies, Monoclonal, Humanized camrelizumab ERBB2 protein, human Receptor, ErbB-2 Trastuzumab
PMC8770537
35069555
Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient
2022